ODI Stock Overview
ODI Pharma AB (publ), a pharmaceutical company, produces and distributes pharmaceutical cannabis and cosmetics products in Europe.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ODI Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr5.70 |
| 52 Week High | kr6.90 |
| 52 Week Low | kr2.88 |
| Beta | 0.54 |
| 1 Month Change | 10.68% |
| 3 Month Change | 11.76% |
| 1 Year Change | 10.68% |
| 3 Year Change | 14.23% |
| 5 Year Change | n/a |
| Change since IPO | -33.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| ODI | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 9.6% | -0.8% | -0.7% |
| 1Y | 10.7% | 55.7% | 4.4% |
Return vs Industry: ODI underperformed the Swedish Pharmaceuticals industry which returned 60% over the past year.
Return vs Market: ODI matched the Swedish Market which returned 10.3% over the past year.
Price Volatility
| ODI volatility | |
|---|---|
| ODI Average Weekly Movement | 7.0% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.1% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: ODI has not had significant price volatility in the past 3 months.
Volatility Over Time: ODI's weekly volatility has decreased from 18% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 1 | Derek Simmross | www.odipharma.com |
ODI Pharma AB (publ), a pharmaceutical company, produces and distributes pharmaceutical cannabis and cosmetics products in Europe. The company offers cannabidiol-infused facial cream, facial mask, and body balm under the Kandol. brand name through kandol.net.
ODI Pharma AB (publ) Fundamentals Summary
| ODI fundamental statistics | |
|---|---|
| Market cap | kr86.75m |
| Earnings (TTM) | -kr3.97m |
| Revenue (TTM) | kr818.38k |
106.0x
P/S Ratio-21.9x
P/E RatioIs ODI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ODI income statement (TTM) | |
|---|---|
| Revenue | kr818.38k |
| Cost of Revenue | kr1.25m |
| Gross Profit | -kr434.28k |
| Other Expenses | kr3.53m |
| Earnings | -kr3.97m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.26 |
| Gross Margin | -53.07% |
| Net Profit Margin | -484.96% |
| Debt/Equity Ratio | 0% |
How did ODI perform over the long term?
See historical performance and comparison